Oxidation of dopamine in the presence of cysteine: Characterization of new toxic products

Chemical Research in Toxicology

Volumn 10, Issue 2, 1997, Pages 147-155

  Shen, Xue Ming ^a   Zhang, Fa ^a   Dryhurst, Glenn ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE DERIVATIVE; DOPAMINE;

ARTICLE; CHEMICAL ANALYSIS; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; OXIDATION; PARKINSON DISEASE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CYSTEINE; DOPAMINE; LETHAL DOSE 50; MALE; MICE; MICE, INBRED ICR; OXIDATION-REDUCTION;

EID: 0031056511     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx960145c     Document Type: Article

References (26)

1. Zhang, F., and Dryhurst, G. (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: New reaction pathways of potential relevance to idiopathic Parkinson's Disease. J. Med. Chem. 37, 1084-1098.
2. Shen, X.-M., and Dryhurst, G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's Disease. Chem. Res. Toxicol. 9, 751-763.
3. Zhang, F., and Dryhurst, G. (1995) Reactions of cysteine and cysteine derivatives with dopamine-o-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine: Potential relevance to idiopathic Parkinson's Disease. Bioorg. Chem. 23, 193-216.
4. Tse, D. C. S., McCreery, R. L., and Adams, R. N. (1976) Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19, 37-40.
5. Zhang, F., and Dryhurst, G. (1993) Oxidation chemistry of dopamine: Possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg. Chem. 21, 392-410.
6. Graham, D. G. (1978) Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
7. Rodgers, A. D., and Curzon, G. (1975) Melanin formation by human brain in vitro. J. Neurochem. 24, 1123-1129.
8. Slivka, A., Mytilineou, C., and Cohen, G. (1987) Histochemical evaluation of glutathione in brain. Brain Res. 409, 275-284.
9. Carstam, R., Brinck, C., Hindemith-Augustsson, A., Rorsman, H., and Rosengren, E. (1991) The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta 1097, 152-160.
10. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Jenner, P., and Marsden, C. D. (1993) Glutathione-related enzymes in brain in basal ganglia degenerative disorders. Ann. Neurol. 36, 356-361.
11. Orlowski, M., and Meister, A. (1979) The y-glutamyl cycle. A possible transport system for amino acids. Proc. Natl. Acad. Sci. U.S.A. 67, 1248-1255.
12. Meister, A. (1974) Glutathione: Metabolism and function via the γ-glutamyl cycle. Life Sci. 15, 177-190.
13. Raps, S. P., Lai, J. C. K., Hertz, L., and Cooper, A. J. L. (1989) Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 493, 398-401.
14. Sagara, J.-L., Miura, K., and Bannai, S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61, 1672-1676.
15. Mann, D. M. A., and Yates, P. O. (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev. 21, 193-203.
16. Hirsch, E. C., Graybiel, A. M., and Agid, Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's Disease. Nature 334, 345-348.
17. Kastner, A., Hirsch, E. C., Lejeune, O., Javoy-Agid, F., Roscol, O., and Agid, Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's Disease related to their neuromelanin content? J. Neurochem. 59, 1080-1089.
18. Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., and Marsden, C. D. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's Disease and Incidental Lewy Body Disease. Ann. Neurol. 32 (Suppl.), S82-S87.
19. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G., Jellinger, K., and Youdim, M. B. H. (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brain. J. Neurochem. 52, 515-520.
20. Dexter, D. T., Sian, J., Jenner, P., and Marsden, C. D. (1993) Implications of alterations in trace element levels in brain in Parkinson's Disease and other neurological disorders affecting the basal ganglia. Adv. Neurol. 60, 273-281.
21. Fornstedt, B., Brun, A., Rosengren, E., and Carlsson, A. (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural. Transm. 1 (P-D Sect.), 279-295.
22. Cheng, F.-C., Kuo, J.-S., Chia, L.-G., and Dryhurst, G. (1996) Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: Possible markers for and potential insights into the pathoetiology of Parkinson's Disease. J. Neural Transm. 103, 433-446.
23. Napolitano, A., Costantini, C., Crescenzi, O., and Prota, G. (1994) Characterization of 1,4-benzothiazine intermediates in the oxidative conversion of 5-S-cysteinyldopa to pheomelanins. Tetrahedron Lett. 35, 6365-6368.
24. Dixon, W. J. (1965) The up-and-down method for small samples. J. Am. Stat. Assoc. 60, 967-978.
25. Fornstedt, B., and Carlsson, A. (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J. Neural Transm. 76, 155-161.
26. Carlsson, A. (1991) Role of brain monoamines and other neurotransmitters in normal and pathological aging. In Alzheimer's and Parkinson's Disease II: Basic and Therapeutic Strategies (Nagatsu, T., Iishee, A., and Yoshida, M., Eds.) Elsevier, New York.